Tag: National Cancer Institute

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026

Laser-sharp Research / chemo resistance, in vitro, in vivo, laser-sharp research, ML7710, ML8500, National Cancer Institute, ovarian cancer, peritoneal carcinoma, photoimmunoconjugates, Photoimmunotherapy, targeted therapies, University of Maryland / March 12, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 The development of chemoresistance presents a major challenge in treating peritoneal metastasis, which often occurs in advanced ovarian cancer. To tackle this, Kaitlyn Moore and teams at University of Maryland and National Cancer Institute evaluated photoimmunotherapy as a solution to inhibit a drug efflux pump on cancer cells [...]

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 Read More »

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy

Scientific papers / 690 nm, in vitro, in vivo, interleukin15, IR700, light activation, ML7710, National Cancer Institute, NIH, NIR, Photoimmunotherapy, PIT, tumor / August 31, 2025

Published in: Cancer Immunology, Immunotherapy Authors: Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Makoto Kano, Miyu Kano, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy Read More »

Protected: Vision-sparing targeted phototherapy for uveal melanoma

subscriber / 689nm, Aura Biosciences, cancer, choroidal melanoma, drug development, drug discovery, medical laser, ML6500, ML6710i, ML7710, MLAKIT, National Cancer Institute, National Institutes of Health, NCI, NIH, ophthalmology, Uveal Melanoma / July 30, 2021

There is no excerpt because this is a protected post.

Protected: Vision-sparing targeted phototherapy for uveal melanoma Read More »

Combining photoimmunotherapy with immune checkpoint inhibition

Application Note / 689nm, in vivo, IRDye700, ML7710, National Cancer Institute, National Institutes of Health, NCI, NIH, oncology, Photoimmunotherapy, PIT, targeted agents / July 14, 2021

Motivation for the study The motivation was to study if photoimmunotherapy could enhance anti-tumor immunity when combined with immune checkpoint inhibition. CD44-targeted photoimmunotherapy was applied against poorly immunogenic, “cold” tumor and antitumor effect was studied alone and in combination with anti-PD-1 immune checkpoint inhibition. Sensitization of this “cold” tumor to immune checkpoint inhibition after photoimmunotherapy

Combining photoimmunotherapy with immune checkpoint inhibition Read More »

ML7710 for photoimmunotherapy against regulatory T cells in tumors

Application Note / cancer, customer, in vivo, Kill cancer, ML7710, Modulight in science, National Cancer Institute, National Institutes of Health, NCI, NIH, oncology, Photoimmunotherapy / June 14, 2021

Results Tumor growth was significantly suppressed by photoimmunotherapy, compared to control or IgG without light activation. Tumor growth suppression, as well as overall survival after photoimmunotherapy, were significantly better with F(ab´)2 fragments than with full IgG. This efficacy improvement might be related to killer T cells, which were detected in much higher numbers

ML7710 for photoimmunotherapy against regulatory T cells in tumors Read More »

Novel antimicrobial phototherapy against emerging infectious diseases

Application Note / anti-infection, antimicrobial, Candida albicans, in vitro, in vivo, ML6500, MRSA, National Cancer Institute, National Institutes of Health, NCI, NIH, pathogen elimination, photoimmuno-antimicrobial strategy, PIAS, The Jikei University School of Medicine, viral particles, wound healing / June 12, 2021

Results PIAS-treated pathogens were effectively eradicated upon NIR illumination. The efficacy of PIAS was dependent on the NIR light dose, 50 J/cm2 eradicating all MRSA from the rat nasal tract (Figure 1). PIAS also saved all mice from fatal MRSA infections, similar to VCM+RFP antibiotics and even more effectively than VCM antibiotics

Novel antimicrobial phototherapy against emerging infectious diseases Read More »